Table 3 Effects (RR and NNT (95% CI)) obtained with different doses of anti-TNFα drugs
|  |  | All doses of anti-TNFα drugs vs. control 4618 vs. 2261* | Recommended doses of anti-TNFα drugs vs. control 2874 vs. 2260** | High-doses drugs vs. control 1169 vs. 921*** of anti-TNFα | Low-doses of anti-TNFα drugs vs. control 251 vs. 252**** | ||||
|---|---|---|---|---|---|---|---|---|---|
Anti-TNFα | ACR | RR (CI 95%) | NNT | RR (CI 95%) | NNT | RR (CI 95%) | NNT | RR (CI 95%) | NNT |
Adalimumab | ACR20 | 1.9 (1.3–2.8) | 6 (5–7) | 2.0 (1.3–2.9) | 5 (4–6) | 3.5 (1.6–7.3) | 3 (2–4) | 2.4 (1.4–4.1) | 5 (4–8) |
|  | ACR50 | 2.7 (1.6–4.4) | 6 (5–7) | 2.8 (1.6–4.7) | 5 (5–6) | 4.7 (1.9–12.0) | 4 (3–5) | 2.9 (1.6–5.1) | 7 (5–13) |
|  | ACR70 | 3.3 (1.8–6.3) | 9 (7–11) | 3.5 (1.9–6.7) | 7 (6–8) | 6.1 (1.8–20.8) | 7 (5–11) | 3.0 (1.1–7.9) | 17 (9–77) |
Etanercept | ACR20 | 1.7 (1.1–2.6) | 7(5–10) | 1.7 (1.1–2.7) | 6 (5–8) | There are no trials with high doses of Etanercept | 4.3 (1.9–10.1) | 3 (2–5) | |
|  | ACR50 | 2.1 (1.1–3.9) | 6 (5–9) | 2.2 (1.1–4.3) | 6 (4–7) |  |  | 4.7 (1.7–13.4) | 6 (4–13) |
|  | ACR70 | 2.0 (0.9–4.4) | NS | 2.1 (0.9–4.5) | NS |  |  | 7.4 (0.9–58.5) | NS |
Infliximab | ACR20 | 1.8 (1.2–2.8) | 5 (4–6) | 1.7 (1.1–2.6) | 5 (4–6) | 2.0 (1.2–3.6) | 5 (4–5) | There are no trials with low doses of Infliximab | |
|  | ACR50 | 2.6 (1.5–4.7) | 5 (5–6) | 2.2 (1.2–4.1) | 6 (5–7) | 2.8 (1.5–5.5) | 5 (4–6) |  |  |
|  | ACR70 | 2.9 (1.4–5.8) | 8 (6–10) | 2.4 (1.2–5.0) | 9 (7–13) | 3.3 (1.5–7.2) | 7 (6–7) |  |  |
Overall | ACR20 | 1.8 (1.4–2.3) | 6 (5–7) | 1.8 (1.4–2.3) | 5 (5–6) | 2.5 (1.5–4.2) | 4 (5–4) | 2.9 (1.7–5.1) | 4 (3–6) |
|  | ACR50 | 2.5 (1.8–3.4) | 6 (5–6) | 2.4 (1.7–3.4) | 5 (5–6) | 3.4 (2.0–5.8) | 5 (4–5) | 3.2 (2.0–5.3) | 6 (5–10) |
|  | ACR70 | 2.8 (1.9–4.2) | 8 (7–9) | 2.7 (1.8–4.1) | 7 (7–9) | 3.9 (2.0–7.6) | 7 (6–8) | 3.5 (1.4–8.6) | 15 (10–38) |